ANGLE plc (LSE:AGL) has entered a collaboration with Myriad Genetics to explore the potential of combining Parsortix-derived circulating tumour cell (CTC) DNA with Myriad’s established tissue-based diagnostic tests. This partnership seeks to enhance patient care by providing broader access to genomic insights through a minimally invasive blood test, supporting advancements in precision medicine.
About ANGLE plc
ANGLE plc is a global leader in liquid biopsy technologies, specializing in circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology applications. Its flagship Parsortix® PC1 System, FDA-cleared, enables detailed analysis, including whole cell imaging and molecular profiling. The company focuses on diagnostic innovation, offering custom assay development and clinical trial support to advance cancer detection and patient treatment.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply